Opinion|Videos|January 13, 2025
ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant
Panelists discuss how the AURIGA trial demonstrates superior outcomes with daratumumab plus lenalidomide maintenance compared with lenalidomide alone after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma while examining key subgroup analyses that inform treatment decisions regarding posttransplant maintenance therapy selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For patients who have received ASCT, please comment on the latest data from the AURIGA trial, evaluating daratumumab plus lenalidomide maintenance in NDMM.
- AURIGA trial, subgroup analysis
- How does the data impact your choice of subsequent treatment, post induction therapy?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
4
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
5